• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Sarcopenia - Pipeline Review, H2 2012 Product Image

Sarcopenia - Pipeline Review, H2 2012

  • Published: October 2012
  • 47 pages
  • Global Markets Direct

Sarcopenia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Sarcopenia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Sarcopenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sarcopenia. Sarcopenia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Sarcopenia.
- A review of the Sarcopenia products under development by companies and universities/research institutes based on information derived from company READ MORE >

2
List of Tables 4
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Sarcopenia Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Sarcopenia 8
Sarcopenia Therapeutics under Development by Companies 10
Sarcopenia Therapeutics under Investigation by Universities/Institutes 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Sarcopenia Therapeutics – Products under Development by Companies 14
Sarcopenia Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Sarcopenia Therapeutics Development 16
F. Hoffmann-La Roche Ltd. 16
Novartis AG 17
Chugai Pharmaceutical Co. Ltd 18
Sarcopenia – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
RG-7686 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Sorafenib1 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Sorafenib4 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Bevacizumab + Sorafenib - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
GC33 + Nexavar - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Gemcitabine + Docetaxel - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Sorafenib + Everolimus - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
tegafur + gimeracil + oteracil potassium - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
tegafur + gimeracil + oteracil potassium - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
S-1 + Interferon Alpha - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Sorafenib + Radiation Therapy - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Lenalidomide - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
pasireotide + everolimus - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
HLA-A-2402 Restricted Antiangiogenic Peptide Vaccine Therapy - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
temsirolimus - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Sarcopenia Therapeutics – Drug Profile Updates 41
Sarcopenia Therapeutics – Discontinued Products 43
Sarcopenia Therapeutics - Dormant Products 44
Sarcopenia – Product Development Milestones 45
Featured News & Press Releases 45
Apr 13, 2010: Endo, Penwest Enter Into Agreement With Barr To Settle Patent Litigation Over Opana ER 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables
Number of Products Under Development for Sarcopenia, H2 2012 8
Products under Development for Sarcopenia – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
F. Hoffmann-La Roche Ltd., H2 2012 16
Novartis AG, H2 2012 17
Chugai Pharmaceutical Co. Ltd, H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Sarcopenia Therapeutics – Drug Profile Updates 41
Sarcopenia Therapeutics – Discontinued Products 43
Sarcopenia Therapeutics – Dormant Products 44

List of Figures
Number of Products under Development for Sarcopenia, H2 2012 8
Products under Development for Sarcopenia – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos